PCM
ZVRA icon

Pentwater Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Pentwater Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-30,409
Closed -$8.94M – 166
2015
Q2 		$8.94M Buy
+30,409
New +$6.63M 0.05% 102

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Pentwater Capital Management's ZVRA Position: Q3 2015 in Review

Pentwater Capital Management sold out of Zevra Therapeutics (ZVRA) in Q3 2015, closing a stake of 30,409 shares — an estimated $8.94M sold.

Pentwater Capital Management first reported a position in ZVRA in Q2 2015 and held it in 1 quarter. The position peaked at $8.94M in Q2 2015. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2015.

  • Pentwater Capital Management reported no remaining Zevra Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Pentwater Capital Management sold 30,409 Zevra Therapeutics shares in Q3 2015, an estimated $8.94M.
  • Pentwater Capital Management first reported a position in Zevra Therapeutics in Q2 2015 and held it in 1 quarter.
  • Pentwater Capital Management's Zevra Therapeutics position peaked at $8.94M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2015.

Based on Pentwater Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.